NAVIDEA BIOPHARMACEUTICALS, INC. (NYSEMKT:NAVB) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
issued a press release regarding its consolidated financial
results for the quarter ended March 31, 2017. A copy of the
Companys May 9, 2017 press release is furnished as Exhibit 99.1
to this Current Report on Form 8-K and is incorporated herein by
reference.
Form 8-K, including exhibit 99.1 attached hereto, shall not be
treated as filed for purposes of the Securities Exchange Act of
1934, as amended.
|
Exhibit
|
|
|
Number
|
Exhibit Description
|
|
99.1
|
Press Release dated May 9, 2017.
|
About NAVIDEA BIOPHARMACEUTICALS, INC. (NYSEMKT:NAVB)
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. NAV5001 is an iodine-123 (I-123) radiolabeled single-photon emission computed tomography (SPECT) imaging agent being developed as an aid in the diagnosis of Parkinson’s disease (PD) and other movement disorders, with potential use as a diagnostic aid in dementia. NAV4694 is a fluorine-18 (F-18) radiolabeled positron emission tomography (PET) imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimer’s disease (AD) and mild cognitive impairment (MCI). NAVIDEA BIOPHARMACEUTICALS, INC. (NYSEMKT:NAVB) Recent Trading Information
NAVIDEA BIOPHARMACEUTICALS, INC. (NYSEMKT:NAVB) closed its last trading session down -0.058 at 0.492 with shares trading hands.
